hrp0097p1-537 | Multisystem Endocrine Disorders | ESPE2023

Effects of seasonal variability of insolation and COVID-19 pandemic isolation on vitamin D concentrations in children

Smyczyńska Joanna , Hilczer Maciej , Łupińska Anna , Pawelak Natalia , Lewiński Andrzej , Stawerska Renata

Introduction: Vitamin D may be considered as a hormone of prohormone of pleiotropic effects. Seasonal variability of insolation affects its synthesis in humans. In our latitude, vitamin D deficiency is widespread. In 2018, updated recommendations for vitamin D supplementation were published in Poland by Rusi&nacute;ska et al. In 2020, SARS-CoV-2 pandemic lockdown was introduced, with suggestions of protective anti-viral vitamin D role.<p class="ab...

hrp0097lb18 | Late Breaking | ESPE2023

A Novel Variant of NR2F2 Associated with Non-syndromic 46,XY DSD

Wankanit Somboon , Zidoune Housna , Bignon-Topalovic Joëlle , Schlick Laurène , Houzelstein Denis , Fusee Leila , McElreavey Kenneth , Bashamboo Anu , Elzaiat Maëva

Differences of sex development (DSD) are congenital conditions with discordance between chromosomal, gonadal and/or anatomic sex. DSD can be syndromic or non-syndromic based on the presence or absence of somatic anomalies, respectively. Variants in several genes have been identified in association with errors of testis determination and male genital differentiation. However, despite technological advances, a genetic diagnosis is not achieved in nearly 50% of individuals presen...

hrp0097p2-312 | Late Breaking | ESPE2023

Clinical and Genotypic characteristics of cases of Congenital Adrenal Hyperplasia due to 11- Beta Hydroxylase Deficiency at Alexandria University Children’s Hospital

Elsayed Shaymaa , Alaa Eldin Thabet Mohamed , Marzouk Eman , Elneely Dalia , Fawzy Dina

Introduction: 11-Beta-hydroxylase deficiency (CYP11B1) is the second most common cause of Congenital Adrenal Hyperplasia (CAH). Although the relative frequency of 11-OHD is reported as 3-5% of the cases of CAH, these numbers may have been somewhat underestimated.(1,2) The resultant clinical picture in 11-OHD is similar to that of 21-OHD, except for the variable presence of hypertension and hypokalemia due to DOC excess.(2,3)Aim o...

hrp0095p1-2 | Adrenals and HPA Axis | ESPE2022

Growth evaluation by applying the QEPS growth model in patients with CAH

Navardauskaite Ruta , Verkauskiene Rasa , Niklasson Aimon , F.M Nierop Andreas , Albertsson-Wikland Kerstin , Holmgren Anton

Objective: Patients with congenital adrenal hyperplasia (CAH) seldom achieve their target height. Early adrenarche may accelerate bone age maturation and affect adult height. The QEPS-growth-model have been used for developing growth references and investigating healthy/pathological growth, however, not before used in individuals with endocrine disorders. This study aimed to evaluate growth patterns in CAH-patients with the QEPS-model.<s...

hrp0095p2-52 | Diabetes and Insulin | ESPE2022

Bone and mineral turnover in newly diagnosed children and adolescents with type 1 diabetes mellitus

Slavcheva-Prodanova Olga , Savova Radka , Archinkova Margarita , Konstantinova Maia

Introduction: There is still controversy about the levels of bone turnover markers at type 1 diabetes (T1D) onset and their dynamics at follow-up. Bonfanti et al. did not find any differences at onset, while few months afterwards beta cross laps level was significantly lower. Pater et al. found lower levels of osteocalcin and Log beta cross laps at onset which normalized after 3 and 12 months. Possible mechanisms are metabolic acidosis, decre...

hrp0089p2-p141 | Fat, Metabolism and Obesity P2 | ESPE2018

Associations between Total Leptin, Bio-inactive Leptin, Soluble Leptin Receptor and Anthropometrics in Children with Severe Early-onset Obesity (SEOO) – the German-Polish Study (EOL-GPS)

Zachurzok Agnieszka , Malecka-Tendera Ewa , Petriczko Elzbieta , Mazur Artur , Pridzun Lutz , Flehmig Bertram , Schnurbein Julia von , Ranke Michael B. , Wabitsch Martin , Brandt Stephanie

Background: Severe early-onset obesity (SEOO) in children is more frequently observed in subjects with genetic disorders of which those of leptin pathway can be analyzed biochemically and genetically.Objectives: The aim of the study was to investigate anthropometrics and leptin parameters, specifically searching for bio-inactive leptin, in children with SEOO.Methods: Study cohort includes children ...

hrp0089p3-p212 | GH &amp; IGFs P3 | ESPE2018

Height Velocity and Height Gain in the First Year of GH Treatment: Predictive Factors of Good Statural Response in Small for Gestational Age (SGA) Patients

Coutant Regis , Leheup Bruno , Nicolino Marc , Salles Jean-Pierre , Hacques Evguenia , Villette Beatrice

Objective: Bang et al. showed that Δ height and growth velocity (GV) the first year of treatment could be predictive factors of statural response in SGA (n=54). Poor responders showed GV <1SDS (55%) and Δ height <0.5SDS (45%). Moreover, Ortego et al. seems to confirm the suitability interest of KIGS mathematical model in a retrospective SGA cohort (n=103) showing that the percentage of good responders in the first year varies betwee...

hrp0089p1-p163 | Growth &amp; Syndromes P1 | ESPE2018

The Association between Growth Hormone Dose and Short-Term Height Outcomes in a Large Cohort of Paediatric Patients with Turner Syndrome: Real-World Data from the NordiNet® International Outcome Study (IOS) and ANSWER Program

Blair Jo , Rohrer Tilman R. , Tonnes Pedersen Birgitte , Roehrich Sebastian , Backeljauw Philippe

Objectives: The recently updated clinical practice guidelines for Turner syndrome (TS) recommend a growth hormone (GH) dose of 45–50 μg/kg/day, increasing to 68 μg/kg/day in case adult height potential is substantially compromised (1). Real-world data on the modifiable factors impacting near-adult height in GH-treated TS patients are limited, but short-term responsiveness to GH has been suggested as one factor (2). We, therefore, analysed the impact of GH dose o...

hrp0089p1-p249 | Thyroid P1 | ESPE2018

Neonatal Screening for Congenital Hypothyroidism: Age-dependent Reference Intervals for Dried Blood Spot TSH in the Neonatal Period

Corbetta Carlo , Angelis Simona De , Rotondi Daniela , Alberti Luisella , Cassini Pamela , Mariani Tiziana , Caiulo Silvana , Vigone Maria Cristina , Weber Giovanna , Olivieri Antonella

Background: National and international guidelines recommend thyrotropin (TSH) determination as the most sensitive test for detecting primary congenital hypothyroidism (CH) in newborn screening programs. A strategy of a second screening at 2 weeks of age, or 2 weeks after the first screening was carried out, is also recommended in preterm, LBW and VLBW neonates, twins, neonates admitted in NICU, and babies with specimen collection within the first 24 hours of life [1–3]. H...

hrp0095fc8.6 | Diabetes and Insulin | ESPE2022

Radio-guided surgery using 68Ga-labelled Exendin in patient with congenital hyperinsulinism

Prasad Vikas , Kühnen Peter , Rothe Karin , Hauptmann Kathrin , Boss Marti , Gotthardt Martin , Brenner Winfried , Beindorff Nicola , Blankenstein Oliver

Congenital hyperinsulinism (CHI) is a life-threatening disease and manifests in the majority of cases in the first days after birth. Based on the distribution of affected cells, focal CHI forms are distinguished from diffuse CHI forms. Focal forms occur in most cases due to a paternally inherited heterozygous mutation in a subunit of an ATP sensitive potassium channel (ABCC8, KCNJ11). Within the diagnostic setting, focal forms can be visualized by 18F DOPA PET scan, as a marke...